{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:14:02Z","timestamp":1791666842351,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>Gastric cancer (GC) is a leading cause of cancer death, occurs predominantly in older age, with increasing incidence in young patients. The Cancer Genome Atlas indicates four subtypes for GC among which Epstein-Barr virus (EBV) subtype is estimated at 8.7%. We aim to determine the prevalence of EBV subtype in young GC patients (\u226445\u2009years) compared with an average-onset cohort (\u226555\u2009years) and characterize the clinicopathologic pattern of young-onset GC.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Gastric cancer samples of patients of both cohorts were screened for EBV by qPCR. Additional staining was done for Human epidermal growth factor receptor 2 (HER2), microsatellite instability (MSI) status and Programmed death-ligand 1 (PD-L1). Demographics and clinical data were retrieved from the medical records.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Thirty-nine young-onset and 35 average-onset GC patients were reviewed. There was no apparent difference in tumor location, family history, histology and HER2 status between the cohorts. More young-onset patients were diagnosed with metastatic disease (27% vs 9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0498). EBV was significantly more prevalent in the young-onset cohort (33% vs 11%, <jats:italic>p<\/jats:italic>\u2009=\u20090.025). 15\/17 EBV positive patients were under the median age of diagnosis for GC in the US (68\u2009years). MSI-H was found only in the average-onset cohort [0% vs 27%, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). PD-L1 positivity was higher in the young-onset cohort (31% vs 3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our study indicates that EBV subtype is more prevalent in young-onset GC and may play a key role in the pathogenesis. Higher rate of PD-L1 positivity in young-onset GC could change treatment strategies. We are currently evaluating these findings in a prospective trial.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-6517-0","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T19:02:41Z","timestamp":1579028561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Young-onset gastric cancer and Epstein\u2013Barr Virus (EBV) \u2013 a major player in the pathogenesis?"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-3729","authenticated-orcid":false,"given":"Assaf","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Hikri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Goshen-Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Barkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Brook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annett","family":"Maderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanoch","family":"Kashtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit Ben","family":"Aharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,14]]},"reference":[{"key":"6517_CR1","volume-title":"American Cancer Society. Cancer Facts & Figures 2011","author":"AC Society","year":"2011","unstructured":"Society AC. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011."},{"key":"6517_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/978-1-60327-492-0_23","volume":"472","author":"H Brenner","year":"2009","unstructured":"Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467\u201377.","journal-title":"Methods Mol Biol"},{"key":"6517_CR3","volume-title":"Stomach Cancer","author":"SSF Sheets","year":"2016","unstructured":"Sheets SSF. Stomach Cancer. 2016. Available from: http:\/seer. cancer. gov\/statfacts\/html\/stomach. html [Last Accessed 28 Dec 2014]."},{"issue":"2","key":"6517_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3748\/wjg.v16.i2.256","volume":"16","author":"HW Chung","year":"2010","unstructured":"Chung HW, Noh SH, Lim JB. Analysis of demographic characteristics in 3242 young age gastric cancer patients in Korea. World J Gastroenterol. 2010;16(2):256\u201363.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"6517_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00423-007-0208-z","volume":"393","author":"J Kulig","year":"2008","unstructured":"Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Jedrys J, Szczepanik AM, et al. Clinicopathological profile and long-term outcome in young adults with gastric cancer: multicenter evaluation of 214 patients. Langenbeck's Arch Surg. 2008;393(1):37\u201343.","journal-title":"Langenbeck's Arch Surg"},{"issue":"1","key":"6517_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5501\/wjv.v1.i1.31","volume":"1","author":"M De Paschale","year":"2012","unstructured":"De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World J Virol. 2012;1(1):31\u201343.","journal-title":"World J Virol"},{"issue":"3","key":"6517_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1053\/j.gastro.2009.05.001","volume":"137","author":"G Murphy","year":"2009","unstructured":"Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824\u201333.","journal-title":"Gastroenterology"},{"key":"6517_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1186\/s12885-015-1813-9","volume":"15","author":"X Liu","year":"2015","unstructured":"Liu X, Liu J, Qiu H, Kong P, Chen S, Li W, et al. Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer. 2015;15:782.","journal-title":"BMC Cancer"},{"issue":"22","key":"6517_CR9","doi-asserted-by":"publisher","first-page":"32925","DOI":"10.18632\/oncotarget.9076","volume":"7","author":"S Derks","year":"2016","unstructured":"Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, et al. Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget. 2016;7(22):32925\u201332.","journal-title":"Oncotarget"},{"issue":"2","key":"6517_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.virol.2003.12.005","volume":"320","author":"ST Oh","year":"2004","unstructured":"Oh ST, Seo JS, Moon UY, Kang KH, Shin D-J, Yoon SK, et al. A naturally derived gastric cancer cell line shows latency I Epstein\u2013Barr virus infection closely resembling EBV-associated gastric cancer. Virology. 2004;320(2):330\u20136.","journal-title":"Virology"},{"issue":"7517","key":"6517_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"4","key":"6517_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1200\/JCO.2004.08.061","volume":"22","author":"J van Beek","year":"2004","unstructured":"van Beek J, zur Hausen A, Klein Kranenbarg E, van de Velde CJ, Middeldorp JM, van den Brule AJ, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol. 2004;22(4):664\u201370.","journal-title":"J Clin Oncol"},{"issue":"15","key":"6517_CR13","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","volume":"23","author":"Bo Hwa Sohn","year":"2017","unstructured":"Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res. 2017. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2211.","journal-title":"Clinical Cancer Research"},{"issue":"31","key":"6517_CR14","doi-asserted-by":"crossref","first-page":"31018","DOI":"10.18632\/oncotarget.5041","volume":"6","author":"HG Lee","year":"2015","unstructured":"Lee HG, Kim H, Kim EJ, Park PG, Dong SM, Choi TH, et al. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation. Oncotarget. 2015;6(31):31018\u201329.","journal-title":"Oncotarget"},{"issue":"1","key":"6517_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/01.pas.0000176428.06629.1e","volume":"30","author":"J van Beek","year":"2006","unstructured":"van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, van de Velde CJ, et al. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol. 2006;30(1):59\u201365.","journal-title":"Am J Surg Pathol"},{"issue":"10111","key":"6517_CR16","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371.","journal-title":"Lancet"},{"issue":"suppl_5","key":"6517_CR17","doi-asserted-by":"publisher","first-page":"v605","DOI":"10.1093\/annonc\/mdx440","volume":"28","author":"ZAJS Wainberg","year":"2017","unstructured":"Wainberg ZAJS, Muro K, Yoon HH, Garrido M, Golan T, Doi T, Catenacci DV, Geva R, Ku G, Bleeker J, Bang Y, Hara H, Chung HC, Savage M, Wang J, Koshiji M, Dalal R, Fuchs CS. KEYNOTE-059 Update: Efficacy and Safety of Pembrolizumab Alone or in Combination With Chemotherapy in Patients With Advanced Gastric or Gastroesophageal cancer. Ann Oncol. 2017;28(suppl_5):v605\u201349. https:\/\/doi.org\/10.1093\/annonc\/mdx440.","journal-title":"Ann Oncol"},{"key":"6517_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/5791262","volume":"2017","author":"Mohamed Abozeid","year":"2017","unstructured":"Abozeid M, Rosato A, Sommaggio R. Immunotherapeutic strategies for gastric carcinoma: a review of preclinical and clinical recent development. Biomed Res Int. 2017;2017:5791262. https:\/\/doi.org\/10.1155\/2017\/5791262.","journal-title":"BioMed Research International"},{"issue":"15_suppl","key":"6517_CR19","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1200\/JCO.2017.35.15_suppl.5504","volume":"35","author":"Antoine Hollebecque","year":"2017","unstructured":"Hollebecque A, Meyer T, Moore KN, Machiels J-PH, De Greve J, L\u00f3pez-Picazo JM, et al. An open-label, multicohort, phase I\/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R\/M) cervical, vaginal, and vulvar cancers. J Clin Oncol. 2017;35(15_suppl):5504. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2017.35.15_suppl.5504.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"6517_CR20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.18632\/oncotarget.2702","volume":"6","author":"YW Zhang","year":"2015","unstructured":"Zhang YW, Zhao XX, Tan C, Zhang ZG, Jiang Y, Chen JN, et al. Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas. Oncotarget. 2015;6(1):207\u201320.","journal-title":"Oncotarget"},{"issue":"9","key":"6517_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/PAI.0000000000000353","volume":"25","author":"C Irkkan","year":"2017","unstructured":"Irkkan C, Balci S, Tezel GG, Akinci B, Yalcin B, G\u00fcler G. Comparison of clinicopathologic parameters and survivals between Epstein-Barr virus\u2013positive and Her2-positive gastric cancers. Appl Immunohistochem Mol Morphol. 2017;25(9):609\u201314.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"45","key":"6517_CR22","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.3748\/wjg.v18.i45.6577","volume":"18","author":"Y Sukawa","year":"2012","unstructured":"Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, et al. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol. 2012;18(45):6577\u201386.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"6517_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4068\/cmj.2017.53.2.140","volume":"53","author":"DW Baek","year":"2017","unstructured":"Baek DW, Kang BW, Hwang S, Kim JG, Seo AN, Bae HI, et al. Clinical significance of p53 protein expression, Beta-catenin expression and HER2 expression for Epstein-Barr virus-associated gastric cancer. Chonnam Med J. 2017;53(2):140\u20136.","journal-title":"Chonnam Med J"},{"issue":"9742","key":"6517_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6517-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:23:30Z","timestamp":1610497410000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6517"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6517-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,14]]},"assertion":[{"value":"23 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study has been approved by the local institutional review board (IRB) committees of Rabin Medical Center and University Medical Center of the Johannes Gutenberg University Mainz. The need for informed consent was waived by the IRBs.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}